In process

Stereotactic body radiation therapy (SBRT) is the established standard of care for medically inoperable early-stage non-small cell lung cancer (ES-NSCLC). When a biopsy is unfeasible, it is often delivered empirically, yet long-term outcomes and failure patterns remain underreported.A total of 56 patients with clinically staged T1-T3N0M0 lung tumors treated with empiric SBRT (2011-2022) were retrospectively analyzed. [...]

There was an error regarding the affiliations for Alexander Roesch. In addition to affiliation 2, the updated affiliations number should include: 2,3..

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract and a key example for targeted therapy with tyrosine kinase inhibitors (TKIs), which have significantly improved survival rates. However, no effective treatments exist for TKI-resistant or mutation-negative tumours. [...]

Understanding the interplay between oncogenic mutations and the tumor microenvironment could help improve therapy for hematological malignancies. We found that the STAT5-activating oncogenes JAK2 p.V617F, FLT3-ITD, and BCR::ABL1 induce oncostatin M (OSM), which triggers disease progression and immunosuppression. [...]

Objective.Proton therapy treatment planning currently needs to account for relatively large range uncertainty margins primarily due to the semi-empirical calibration of the treatment planning x-ray computed tomography (CT) to proton stopping power relative to water (RSP). Proton radiography enables direct measurement of integral RSP, offering potential to improve calibration and reduce these uncertainties.Approach.Three deep neural network architectures are trained to infer a patient RSP map using the treatment planning CT and proton radiographies, assuming straight proton trajectories. [...]

Lipocalin-2 (LCN2) performs pleiotropic and tumor context-dependent functions in cancers of diverse etiologies. In prostate cancer (PCa) cells, LCN2 regulates distinct phenotypic features, including cytoskeleton organization and expression of inflammation mediators. [...]

mAb-based blocking of the immune checkpoints involving the CTLA4-B7 and PD1-PDL1 inhibitory axes enhance T-cell-based adaptive immune responses in patients with cancer. We show here that antitumor responses by natural killer (NK) cells can be enhanced by a checkpoint-blocking mAb, 14-25-9, which we developed against proliferating cell nuclear antigen (PCNA). [...]

The Ebola Virus (EBOV) glycoprotein (GP) sterically shields cell-membrane ligands to immune receptors such as human leukocyte antigen class-1 (HLA-I) and MHC class I polypeptide-related sequence A (MICA), thus mediating immunity evasion. It was suggested that the abundant N-glycosylation of the EBOV-GP is involved in this steric shielding. [...]

Despite of remarkable progress made in the head and neck cancer (HNC) therapy, the survival rate of this metastatic disease remain low. Tailoring the appropriate therapy to patients is a major challenge and highlights the unmet need to have a good preclinical model that will predict clinical response. [...]

Environmental conditions greatly shape the phenotype and function of immune cells. Specifically, hypoxic conditions that exist within tissues and organs have been reported to affect both the adaptive and the innate immune system. [...]